SCHEMBL18857604

SCHEMBL18857604

CC(C)CCC(=O)N[C@@H](Cc1cnc[nH]1)C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A5 Q9Y345 1/20 0.50
▸ REN P00797 5/20 0.49
▸ ERAP2 Q6P179 1/20 0.48
▸ ERAP1 Q9NZ08 1/20 0.48
▸ LNPEP Q9UIQ6 1/20 0.48
▸ SLC15A2 Q16348 1/20 0.48
▸ HRH3 Q9Y5N1 5/20 0.46
▸ HRH4 Q9H3N8 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ GLA P06280 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ THPO P40225 1/20 0.46
▸ CYP3A4 P08684 1/20 0.45
▸ SLC7A5 Q01650 1/20 0.45
▸ ITGB2 P05107 1/20 0.45
▸ ICAM1 P05362 1/20 0.45
▸ ITGAL P20701 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22722176 0.89 REN (0.58) SLC6A5RENERAP2ERAP1LNPEP
SCHEMBL18862330 0.86 REN (0.55) SLC6A5RENERAP2ERAP1LNPEP
SCHEMBL17325320 0.82 SLC6A5 (0.55) SLC6A5RENSLC15A2HRH4CYP3A4
SCHEMBL18857761 0.81 SLC15A2 (0.58) SLC6A5SLC15A2HRH3HRH4EPHX2
SCHEMBL18857595 0.80 REN (0.47) RENERAP2ERAP1LNPEPHRH3
SCHEMBL18381347 0.80 SLC6A5 (0.61) SLC6A5SLC15A2ALDH1A1CYP1A2CYP3A4
SCHEMBL20956607 0.80 SLC6A5 (0.70) SLC6A5SLC15A2HRH3ALDH1A1CYP1A2
SCHEMBL16364168 0.80 CYP3A4 (0.54) SLC6A5RENSLC15A2HRH3HRH4
SCHEMBL19051548 0.79 REN (0.57) SLC6A5RENERAP2ERAP1LNPEP
SCHEMBL18862465 0.79 SLC15A2 (0.53) SLC6A5RENERAP2ERAP1LNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023225661-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-11-23 — — WO disclosed
US-20210139892-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF RNA TO A CELL THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-05-13 — — US disclosed
US-10851367-B2 Tissue-specific genome engineering using CRISPR-Cas9 PFIZER INC. (US) 2020-12-01 — — US disclosed
WO-2017083368-A9 TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 PFIZER INC. (US) 2018-04-12 — — WO disclosed
US-20170137801-A1 TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-05-18 — — US disclosed
WO-2017083368-A1 TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 PFIZER INC. (US) 2017-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851367-B2 Tissue-specific genome engineering using CRISPR-Cas9 ASGR1, LDLR, HAVCR2 SLC6A5 3967/4885REN 2795/4885ERAP2 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback